Bavarian Nordic's MVA-BN® Vaccine Platform Selected by U.S. Department of Defense for New Vaccine Development

| Source: Bavarian Nordic A/S
KVISTGAARD, Denmark, February 21, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) announced today that its MVA-BN vaccine platform technology has been
selected by the Defense Threat Reduction Agency (DTRA), a part of the United
States Department of Defense, for the development of a vaccine against two
potential biological threats to national security - Burkholderia pseudomallei
and Burkholderia mallei.

"The award of this contract illustrates the strength of our MVA-BN vaccine
platform technology, which has been developed through a decade-long partnership
with the U.S. Department of Health and Human Services," said Anders Hedegaard,
President and CEO of Bavarian Nordic. "As part of our strategy to expand our
biodefense business beyond smallpox, we are pleased to add DTRA to our list of
government partners with whom we work to develop novel biodefense vaccines."

DTRA is the fourth U.S. Government agency to collaborate with Bavarian Nordic on
the development of novel biodefense vaccines. Other ongoing collaborations
include the development of vaccines against smallpox, filoviruses (Ebola and
Marburg) and foot-and-mouth disease, for which the company has received funding
from the Biomedical Advanced Research and Development Authority, the National
Institute of Allergy and Infectious Diseases, and the Department of Homeland
Security's Science and Technology Directorate.

Under this new USD 0.5 million contract Bavarian Nordic will design, generate
and test MVA-BN-based recombinant vaccines against Burkholderia. If the contract
yields a successful proof of concept, DTRA may support further development of
the vaccine through a larger contract award.

Asger Aamund
Chairman of the Board

Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
Paul Chaplin, President, Infectious Diseases Division. Phone 202-288-9220

About Burkholderia
Burkholderia pseudomallei and Burkholderia mallei are bacterial pathogens that
have been determined to pose a material threat sufficient to affect the United
States' national security. B. pseudomallei causes melioidosis, a human disease
endemic in Southeast Asia and northern Australia. B. mallei causes glanders, a
zoonotic disease primarily occurring in Africa, Asia, the Middle East, and
Central/South America. Because of the lengthy antibiotic therapy required to
treat melioidosis and glanders, the suboptimal clinical outcomes, possible
biothreat applications, and public health implications, there is significant
interest in developing new vaccines capable of protecting against these agents,
for which effective vaccines do not currently exist.

About MVA-BN Platform Technology
MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) is a robust and adaptable
vaccine platform suitable for addressing a wide variety of infectious diseases.
In addition to developing MVA-BN as a safer smallpox vaccine essential to
protecting the immune-compromised population, Bavarian Nordic has conducted
preclinical and clinical studies of recombinant MVA-BN-based vaccines for a
variety of infectious diseases and numerous types of cancer. More than 7,300
individuals, nearly 1,000 of whom are immunocompromised, have been vaccinated
with MVA-BN-based vaccines, showing the platform displays high immunogenicity
and a favorable safety profile.

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious diseases.
Lead product candidates are PROSTVAC®, an immunotherapy product candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3
clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in
Phase 3 development, which is being developed and supplied for emergency use to
the U.S. Strategic National Stockpile under a contract with the U.S. Government.
The vaccine is approved in Canada under the trade name IMVAMUNE and in the
European Union under the trade name IMVANEX®.

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level
1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visit

This material is based upon work supported by the Defense Threat Reduction
Agency under Contract No. HDTRA-1-14-C-0017. Any opinions, findings and
conclusions or recommendations expressed in this material are those of the
author(s) and do not necessarily reflect the views of the Defense Threat
Reduction Agency.

Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.